FINANCIAL PERFORMANCE (9M Ended 9/30/2025) Revenue grew 15.8% to \(2.37B (\)1.835B Screening, \(533.9M Precision Oncology), with quarterly revenue accelerating nearly 20% to \)851M. Despite remaining unprofitable, the Net Loss narrowed substantially across both quarterly (\((19.6)M vs. \)(38.2)M YoY) and nine-month periods (\((122.0)M vs. \)(164.3)M YoY), reflecting improved operational leverage, though Sales & Marketing spending increased significantly. Operating Cash Flow more than doubled to \(339.7M. Total Stock-Based Compensation expense was \)162.0M YTD, with $348.8M in unrecognized costs expe
...